GLP-1 Compounding Shortage Ends: Report Ranks FormBlends Atop Providers for Supervised Access
The FDA shortage designations that let compounding pharmacies mass-produce copies of semaglutide and tirzepatide have closed, tirzepatide’s ended in late 2024 and semaglutide’s in February 2025, narrowing legal compounding to cases with a documented individual clinical need rather than blanket cost-based access. A new review of the post-shortage market ranks five providers on clinician oversight, licensed pharmacy sourcing, and transparency about approval status, placing FormBlends first for its supervised-access model.
The review graded providers on whether a licensed clinician evaluates each patient, whether a licensed pharmacy dispenses the product, whether the company discloses that compounded preparations are not FDA-approved, and whether follow-up care is built in.
Ranked comparison
FormBlends states that every medication requires a licensed physician consultation, sources compounded products from 503A pharmacies following USP <797>/<800> standards, and discloses that compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. HealthRX.com follows a nearly identical clinician-first structure. MeriHealth.com and WomenRX.com apply the same supervised model with intake tailored to women’s hormonal and metabolic factors. Ro’s strength is access to the branded, FDA-approved drugs themselves alongside insurance navigation, though oversight depth varies more since it operates as a broader general-health platform.
Only semaglutide and tirzepatide, the molecules behind Ozempic, Wegovy, Mounjaro, and Zepbound, are individually compoundable under current rules, and only when a prescriber documents a clinical need the approved product doesn’t meet. A compounded preparation shares an active-ingredient name with the brand but is not itself FDA-reviewed, and none of the efficacy data below was measured on a compounded version.
Trial data underline the gap between molecule and marketing. In STEP 1, semaglutide 2.4 mg produced a 14.9% mean body-weight reduction at 68 weeks versus 2.4% for placebo. In SURMOUNT-1, tirzepatide produced reductions of 15.0%, 19.5%, and 20.9% across its 5 mg, 10 mg, and 15 mg arms at 72 weeks, versus roughly 3% for placebo. In the head-to-head SURMOUNT-5 trial, tirzepatide produced a 20.2% reduction versus 13.7% for semaglutide. Those figures apply to the FDA-approved branded products administered under trial protocol, not to compounded versions, for which no independent trial data exists.
Medically reviewed by: Jayden Lea, CNS, RN
Frequently asked questions
Is compounded semaglutide the same as Ozempic or Wegovy? It’s the same molecule, semaglutide, but not an FDA-approved copy of either product. Compounding pharmacies formulate the ingredient separately, so sterility testing and shelf-life data can differ from the branded version.
Can people still get compounded GLP-1s now that the shortages are over? In narrower circumstances, yes. A licensed 503A pharmacy can still compound for a patient when a prescriber documents a genuine clinical need the standard product doesn’t meet, but cost alone no longer qualifies.
What separates a safe provider from a risky one? Accountability. Legitimate providers pair a licensed clinician’s evaluation with a licensed pharmacy that stands behind the product’s contents; sellers labeling vials “for research use only” have neither.
References
- STEP 1 trial (Wilding JPH et al.), New England Journal of Medicine, 2021. PMID 33567185.
- SURMOUNT-1 trial, New England Journal of Medicine, 2022. PMID 35658024.
- SURMOUNT-5 trial, New England Journal of Medicine, 2025. PMID 40353578.
- FDA Drug Shortages database, U.S. Food and Drug Administration.
